Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Kohn Website

Elise C. Kohn, M.D.

Selected Publications
1)  Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J. Clin. Oncol. 26: 3709-14, 2008. [Journal]
2)  Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, Flugy AM, Santoro A, Kohn EC, De Leo G.
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
J. Cell. Physiol. 215: 111-21, 2008. [Journal]
3)  Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC.
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Cancer. 112: 1726-32, 2008. [Journal]
4)  Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC, Pommier Y.
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
Mol. Cancer Ther. 7: 10-8, 2008. [Journal]
5)  Coleman RL, Kohn EC.
Rationale for combination use of targeted agents in ovarian cancer: Do we have one?.
Cancer. 113(4): 665-667, 2008. [Journal]
6)  Yang JL, Qu XJ, Yu Y, Kohn EC, Friedlander ML.
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Int. J. Cancer. 123: 258-63, 2008. [Journal]
7)  Simpkins FA, Devoogdt NM, Rasool N, Tchabo NE, Alejandro EU, Kamrava MM, Kohn EC.
The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
Carcinogenesis. 29: 466-72, 2008. [Journal]
8)  Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC.
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Cancer. 109: 1323-30, 2007. [Journal]
9)  Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC.
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
Cancer. 110: 309-17, 2007. [Journal]
10)  Annunziata CM, Kleinberg L, Davidson B, Berner A, Gius D, Tchabo N, Steinberg SM, Kohn EC.
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.
Clin. Cancer Res. 13: 6585-92, 2007. [Journal]
11)  Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G.
Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines.
J. Proteome Res. 6: 4330-42, 2007. [Journal]
12)  Winters M, Dabir B, Yu M, Kohn EC.
Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays.
Proteomics. 7: 4066-8, 2007. [Journal]
13)  Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G.
Proteomics as a tool for biomarker discovery.
Dis. Markers. 23: 411-7, 2007. [Journal]
14)  Gunn AJ, Hama Y, Koyama Y, Kohn EC, Choyke PL, Kobayashi H.
Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore.
Cancer Sci. 98: 1727-33, 2007. [Journal]
15)  Dhamoon AS, Kohn EC, Azad NS.
The ongoing evolution of proteomics in malignancy.
Drug Discov. Today. 12: 700-8, 2007. [Journal]
16)  Kohn E. Kufe DW, Pollock R, Weicheselbaum R, Bast R, Gansler C, Holland JF, Frei E, eds.
Invasion and Metastasis. In: Cancer Medicine 7. Volume .
Hamilton and London: B. C. Decker; 2006. p. 148-156 [Book Chapter]
17)  Annunziata C, Roque DM, Azad N, Kohn E. Daoud S, eds.
Application of werum and tissue proteomics to understand and detect solid tumors. In: Proteomics in Cancer Therapy. Volume .
Totowa, NJ: Humana Press; 2006. p. in press [Book Chapter]
18)  Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND.
10th Biennial Helene Harris Memorial Trust meeting.
Cancer Res. 66: 2904-6, 2006. [Journal]
19)  Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Mol. Cancer Ther. 5: 2613-23, 2006. [Journal]
20)  Kassis JN, Guancial EA, Doong H, Virador V, Kohn EC.
CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins.
Exp. Cell Res. 312: 2962-71, 2006. [Journal]
21)  Kassis JN, Guancial EA, Doong H, Virador V, Kohn EC.
CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins.
Exp. Cell Res. 312: 2962-71, 2006. [Journal]
22)  Alessandro R, Di Bella MA, Flugy AM, Fontana S, Damiani F, Corrado C, Colomba P, Todaro M, Russo D, Santoro A, Kohn EC, De Leo G.
Comparative study of T84 and T84SF human colon carcinoma cells: in vitro and in vivo ultrastructural and functional characterization of cell culture and metastasis.
Virchows Arch. 449: 48-61, 2006. [Journal]
23)  Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer Biol. Ther. 5: 22-7, 2006. [Journal]
24)  Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC.
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Clin. Cancer Res. 12: 791-9, 2006. [Journal]
25)  Azad NS, Rasool N, Annunziata CM, Minasian L, Whitely G, Kohn EC.
Proteomics in clinical trials and practice: present uses and future promise.
Mol Cell Proteomics. 5(10): 1819-1829, 2006. [Journal]
26)  Simpkins F, Espina V, Posadas E, Petricoin EF, Liotta L, Kohn EC.
Protein arrays for clinical proteomics and signal transduction profiling. In: Proteomics in Cancer Research. Volume .
Wiley; 2005. In Press. [Book Chapter]
27)  Tchabo N, Guancial E, Czechowicz J, Kohn E.
The role of proteomics in the diagnosis and treatment of ovarian cancer.
Women's Health. 2005. In Press. [Journal]
28)  Tchabo NE, Liel MS, Kohn EC.
Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
Am J Pharmacogenomics. 5: 141-8, 2005. [Journal]
29)  Perabo FG, Demant AW, Wirger A, Schmidt DH, Sitia M, Wardelmann E, Müller SC, Kohn EC.
Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model.
Anticancer Res. 25: 725-9, 2005. [Journal]
30)  Hoffmann S, He S, Jin ML, Masiero L, Wiedemann P, Ryan SJ, Kohn EC.
Carboxyamido-triazole modulates retinal pigment epithelial and choroidal endothelial cell attachment, migration, proliferation, and MMP-2 secretion of choroidal endothelial cells.
Curr Eye Res. 30: 103-13, 2005. [Journal]
31)  Cruysberg LP, Franklin AJ, Sanders J, Self C, Yuan P, Csaky KG, Robinson MR, Kohn EC, Edelhauser HF.
Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2).
Retina (Philadelphia, Pa.). 25: 1022-31, 2005. [Journal]
32)  Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B.
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
Cancer. 103: 2313-9, 2005. [Journal]
33)  Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn EC.
Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer.
Oncogene. 2005. [Journal]
34)  Kohn EC, Travers LA, Kassis J, Broome U, Klominek J.
Malignant effusions are sources of fibronectin and other promigratory and proinvasive components.
Diagn. Cytopathol. 33: 300-8, 2005. [Journal]
35)  Boyce EA, Kohn EC.
Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Int. J. Gynecol. Cancer. 15 Suppl 3: 266-73, 2005. [Journal]
36)  Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC.
Proteomic analysis for the early detection and rational treatment of cancer--realistic hope?.
Ann Oncol. 16: 16-22, 2005. [Journal]
37)  Alessandro R, Belluco C, Kohn EC.
Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery.
Clin Colorectal Cancer. 4: 396-402, 2005. [Journal]
38)  Alessandro R, Kohn EC, Fontana S, De Leo G.
Proteomic strategies and their application in cancer research.
Tumori. 91: 447-455, 2005. [Journal]
39)  Simpkins F, Czechowicz JA, Liotta L, Kohn EC.
SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics.
Pharmacogenomics. 6: 647-53, 2005. [Journal]
40)  Winters ME, Mehta AI, Petricoin EF, Kohn EC, Liotta LA.
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Cancer Res. 65: 3853-60, 2005. [Journal]
41)  Kassis J, Klominek J, Kohn EC.
Tumor microenvironment: what can effusions teach us?.
Diagn. Cytopathol. 33: 316-9, 2005. [Journal]
42)  Miller WJ, Kayton ML, Patton A, O'Connor S, He M, Vu H, Baibakov G, Lorang D, Knezevic V, Kohn E, Alexander HR, Stirling D, Payvandi F, Muller GW, Libutti SK.
A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay.
J Transl Med. 2: 4, 2004. [Journal]
43)  Liotta LA, Kohn E.
Anoikis: cancer and the homeless cell.
Nature. 430: 973-4, 2004. [Journal]
44)  Franklin AJ, Jetton TL, Kuchemann CL, Russell SR, Kohn EC.
CAI is a potent inhibitor of neovascularization and imparts neuroprotection in a mouse model of ischemic retinopathy.
Invest Ophthalmol Vis Sci. 45: 3756-66, 2004. [Journal]
45)  Perabo FG, Wirger A, Kamp S, Lindner H, Schmidt DH, Müller SC, Kohn EC.
Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2.
Anticancer Res. 24: 2869-77, 2004. [Journal]
46)  Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC.
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Cancer. 100: 2139-47, 2004. [Journal]
47)  Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G, Barrett JC, Liotta LA, Petricoin EF, Veenstra TD.
High-resolution serum proteomic features for ovarian cancer detection.
Endocr Relat Cancer. 11: 163-78, 2004. [Journal]
48)  Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB.
Molecular therapeutics: promise and challenges.
Semin Oncol. 31: 39-53, 2004. [Journal]
49)  Posadas EM, Davidson B, Kohn EC.
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
Curr Opin Oncol. 16: 478-84, 2004. [Journal]
50)  Stevens EV, Posadas EM, Davidson B, Kohn EC.
Proteomics in cancer.
Ann Oncol. 15 Suppl 4: iv167-71, 2004. [Journal]
51)  Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ.
Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.
Hum Pathol. 35: 934-48, 2004. [Journal]
52)  Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G.
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Semin. Oncol. 30: 93-104, 2003. [Journal]
53)  Kohn EC, Mills GB, Liotta L.
Promising directions for the diagnosis and management of gynecological cancers.
Int J Gynaecol Obstet. 83 Suppl 1: 203-9, 2003. [Journal]
54)  Sieczkiewicz GJ, Hussain M, Kohn EC.
Angiogenesis and metastasis.
Cancer Treat. Res. 107: 353-81, 2002. [Journal]
55)  Doong H, Price J, Kim YS, Gasbarre C, Probst J, Liotta LA, Blanchette J, Rizzo K, Kohn E.
CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70.
Oncogene. 19: 4385-95, 2000. [Journal]
56)  Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK.
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Microvasc. Res. 60: 70-80, 2000. [Journal]
57)  Brown MR, Kohn EC, Hutter RV.
The new millennium: applying novel technology to the study of the cancer cell in situ.
Cancer. 88: 2-5, 2000. [Journal]
58)  Brown MR, Chuaqui R, Vocke CD, Berchuck A, Middleton LP, Emmert-Buck MR, Kohn EC.
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
Gynecol. Oncol. 74: 98-102, 1999. [Journal]
59)  Masiero L, Lapidos KA, Ambudkar I, Kohn EC.
Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: role of calcium influx.
J. Cell. Sci. 112 ( Pt 19): 3205-13, 1999. [Journal]
60)  Sandor V, Reed E, Sarosy G, Middleton LP, Davis P, Kohn E.
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival.
Ann. Oncol. 10: 585-8, 1999. [Journal]
61)  Peterson LA, Brown MR, Carlisle AJ, Kohn EC, Liotta LA, Emmert-Buck MR, Krizman DB.
An improved method for construction of directionally cloned cDNA libraries from microdissected cells.
Cancer Res. 58: 5326-8, 1998. [Journal]
62)  Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC.
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Cancer. 83: 1980-8, 1998. [Journal]
63)  Kohn EC.
Endostatin and angiostatin: the next anti-angiogenesis generation.
Angiogenesis. 2: 25-7, 1998. [Journal]
64)  Luzzi KJ, Varghese HJ, MacDonald IC, Schmidt EE, Kohn EC, Morris VL, Marshall KE, Chambers AF, Groom AC.
Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI).
Angiogenesis. 2: 373-9, 1998. [Journal]
65)  Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, Figg WD.
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Journal of pharmacokinetics and biopharmaceutics. 26: 673-87, 1998. [Journal]
66)  Wu Y, Palad AJ, Wasilenko WJ, Blackmore PF, Pincus WA, Schechter GL, Spoonster JR, Kohn EC, Somers KD.
Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.
Clin. Cancer Res. 3: 1915-21, 1997. [Journal]
67)  Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC.
Ovarian cancer in the proteomics era.
Int. J. Gynecol. Cancer. 18 Suppl 1: 1-6, , ,. [Journal]
68)  Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS.
Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium.
Int. J. Gynecol. Cancer. 16: 463-9, , ,. [Journal]
69)  Stevens EV, Liotta LA, Kohn EC.
Proteomic analysis for early detection of ovarian cancer: a realistic approach?.
Int. J. Gynecol. Cancer. 13 Suppl 2: 133-9, , ,. [Journal]
70)  Alessandro R, Fontana S, Kohn E, De Leo G.
Proteomic strategies and their application in cancer research.
Tumori. 91: 447-55, , ,. [Journal]
71)  Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC.
CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins.
J Biol Chem. 278: 28490-500, 2003. [Journal]
72)  Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, Kohn EC.
The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer.
Clin Cancer Res. 9: 44-51, 2003. [Journal]
73)  Liotta LA, Kohn EC.
The microenvironment of the tumour-host interface.
Nature. 411: 375-9, 2001. [Journal]
74)  Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA.
Use of proteomic patterns in serum to identify ovarian cancer.
Lancet. 359: 572-7, 2002. [Journal]
75)  Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC.
A phase II trial of carboxyamido-triazole (CAI) in patients with relapsed epithelial ovarian cancer.
JOURNAL OF CLINICAL ONCOLOGY. 21: 4356-63, 2003. [Journal]
76)  Romano MF, Festa M, Petrella A, Rosati A, Pascale M, Bisogni R, Poggi V, Kohn EC, Venuta S, Turco MC, Leone A.
BAG3 protein regulates cell survival in childhood acute lymphoblastic leukemia cells.
Cancer Biology and Therapy. 2: 508-510, 2003. [Journal]
77)  Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC.
Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
J Cell Physiol. 197: 139-48, 2003. [Journal]
78)  Liotta LA, Kohn EC, Petricoin EF.
Clinical proteomics: personalized molecular medicine.
JAMA. 286: 2211-4, 2001. [Journal]
79)  Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF.
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Proteomics. 2: 76-84, 2002. [Journal]
80)  Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC.
Granulin-epithelin precursor (GEP) is a novel progostsic marker in epithelial ovarian cancer.
CANCER. in press, 2004. [Journal]
81)  Moody TW, Chiles J, Moody E, Sieczkiewicz GJ, Kohn EC.
CAI inhibits the growth of small cell lung cancer cells.
Lung Cancer. 39: 279-88, 2003. [Journal]
82)  Patton AM, Kassis J, Doong H, Kohn EC.
Calcium as a molecular target in angiogenesis.
Curr Pharm Des. 9: 543-51, 2003. [Journal]
83)  Liotta LA, Kohn EC.
Cancer's deadly signature.
Nat Genet. 33: 10-1, 2003. [Journal]
84)  Liotta LA, Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC.
General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer.
Gynecol Oncol. 88: S25-8; discussion S37-42, 2003. [Journal]
85)  Annunziata CM, Kohn EC.
Is there a genomic basis for primary chemoresistance in ovarian cancer?.
Gynecol Oncol. 90: 1-2, 2003. [Journal]
86)  Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF.
Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer.
Proteomics. 3: 1801-10, 2003. [Journal]
87)  D'Amato M, Flugy AM, Alaimo G, Bauder B, Kohn EC, De Leo G, Alessandro R.
Role of calcium in E-selectin induced phenotype of T84 colon carcinoma cells.
Biochem Biophys Res Commun. 301: 907-14, 2003. [Journal]
88)  Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J.
Specific keynote: molecular therapeutics in ovarian cancer.
Gynecol Oncol. 88: S88-92; discussion S93-6, 2003. [Journal]
89)  Jones MB, Spooner M, Kohn EC.
The granulin-epithelin precursor: a putative new growth factor for ovarian cancer.
Gynecol Oncol. 88: S136-9, 2003. [Journal]
90)  Grove AD, Prabhu VV, Young BL, Lee FC, Kulpa V, Munson PJ, Kohn EC.
Both protein activation and gene expression are involved in early vascular tube formation in vitro.
Clin Cancer Res. 8: 3019-26, 2002. [Journal]
91)  Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA.
Clinical proteomics: translating benchside promise into bedside reality.
Nat Rev Drug Discov. 1: 683-95, 2002. [Journal]
92)  Flugy AM, D'Amato M, Russo D, Di Bella MA, Alaimo G, Kohn EC, De Leo G, Alessandro R.
E-selectin modulates the malignant properties of T84 colon carcinoma cells.
Biochem Biophys Res Commun. 293: 1099-106, 2002. [Journal]
93)  Michener CM, Ardekani AM, Petricoin EF, Liotta LA, Kohn EC.
Genomics and proteomics: application of novel technology to early detection and prevention of cancer.
Cancer Detect Prev. 26: 249-55, 2002. [Journal]
94)  Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK.
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
Biotechniques. 33: 664-6, 668, 670, 2002. [Journal]
95)  Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA.
Serum proteomic patterns for detection of prostate cancer.
J Natl Cancer Inst. 94: 1576-8, 2002. [Journal]
96)  Alessandro R, Kohn EC.
Signal transduction targets in invasion.
Clin Exp Metastasis. 19: 265-73, 2002. [Journal]
97)  Liotta LA, Kohn EC.
Stromal therapy: the next step in ovarian cancer treatment.
J Natl Cancer Inst. 94: 1113-4, 2002. [Journal]
98)  Doong H, Vrailas A, Kohn EC.
What's in the 'BAG'?--A functional domain analysis of the BAG-family proteins.
Cancer Lett. 188: 25-32, 2002. [Journal]
99)  Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA.
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Clin Cancer Res. 7: 1600-9, 2001. [Journal]
100)  Perabo FG, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, Wirger A, Pegelow K, Albers P, Kohn EC, von Ruecker A, Mueller SC.
Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.
Br J Cancer. 84: 1330-8, 2001. [Journal]
101)  Mills GB, Lu Y, Kohn EC.
Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.
Proc Natl Acad Sci U S A. 98: 10031-3, 2001. [Journal]
102)  Lapidos KA, Woodhouse EC, Kohn EC, Masiero L.
Mg(++)-induced endothelial cell migration: substratum selectivity and receptor-involvement.
Angiogenesis. 4: 21-8, 2001. [Journal]
103)  Brown MR, Blanchette JO, Kohn EC.
Angiogenesis in ovarian cancer.
Baillieres Best Pract Res Clin Obstet Gynaecol. 14: 901-18, 2000. [Journal]
104)  Hodgson L, Kohn EC, Dong C.
Extracellular lipid-mediated signaling in tumor-cell activation and pseudopod protrusion.
Int J Cancer. 88: 593-600, 2000. [Journal]

This page was last updated on 9/20/2008.